Catalyst Biosciences
Drug r&d company creating catalytic biopharmaceutical products based on engineered human proteases.
HQ location
South San Francisco, United States
Website
Launch date
Employees
Market cap
$312m
Enterprise value
$315m
Share price
$16.14 CBIO
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Sofinnova(exited)
Morgenthaler Ventures(exited)
HealthCare Ventures(exited)
Essex Woodlands Health Ventures(exited)
Burrill(exited)
Pfizer(exited)
Auriga Partners(exited)
Auriga Partners (Paris)(exited)
Academy Venture Fund(exited)
Advent Venture Partners(exited)
CDC IXIS Innovation(exited)
CDIB BioScience Ventures(exited)
EuclidSR Partners(exited)
NEA(exited)
EW Healthcare Partners(exited)
Novartis Venture Fund(exited)
Avoro Capital Advisors(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (99 %) | - | - | (65 %) | (89 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2127 %) | (561217 %) | - | (274 %) | (1194 %) | (6568 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2118 %) | (500917 %) | - | (268 %) | (1198 %) | (1038 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1262 % | 357900 % | - | 253 % | 939 % | 1642 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.